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Background/aim: We aimed to define the effect of tumor size on recurrence and survival rates in patients with stage I–II endometrioidtype endometrial cancer.
Materials and methods: A total of 550 patients who had total abdominal hysterectomy, bilateral salpingo-oophorectomy, and pelvicparaaortic lymphadenectomy were included. Patients with extrauterine spread, sarcomatous components, or synchronized tumor and
those who did not undergo lymphadenectomy or did not have data on tumor size were excluded.
Results: The median tumor size was 35 mm (range: 3–335 mm). According to the 2009 International Federation of Obstetrics and
Gynecology (FIGO) criteria, 245 cases were defined as stage IA, 271 as stage IB, and 34 as stage II. The 5-year disease-free survival (DFS)
rate was 92% and the 5-year disease-specific survival (DSS) rate was 99%. The effects of prognostic factors on DFS were evaluated. Older
age, stage II disease, deep myometrial invasion, and receiving adjuvant radiotherapy were associated with decreased DFS. There was no
statistically significant association between tumor size and DFS. The 5-year DFS for patients with a tumor diameter of <35 mm, which
was the median tumor size of the entire group, was 94%, while it was 89% for patients having a tumor diameter of >35 mm (P = 0.128).
Conclusion: Tumor size was not a risk factor predicting recurrence in patients with stage I or II endometrioid-type endometrial cancer
who had lymphadenectomy.
Key words: Tumor size, lymphadenectomy, endometrial cancer

1. Introduction
Endometrial cancer (EC) is the most common malignancy
of the female genital tract in developed countries, with
80% of newly diagnosed patients having endometrioidtype tumors [1,2]. The tumor is limited to the uterine
corpus in 70% of patients at the time of initial diagnosis,
and patients with early-stage and low-grade tumors have a
5-year survival rate over 90% [3,4]. Age, cancer stage, cell
type, grade, depth of myometrial invasion, the presence
of cervical invasion, and presence of nodal/nonnodal
extrauterine disease are the major clinical and surgical
factors determining recurrence and survival rates in EC
[5,6].
Tumor size, which is another prognostic factor, is
associated with poor surgicopathological factors, primarily
with lymphatic spread [7–9]. However, the relationship

between tumor size and recurrence and survival rates is
not clear. Todo et al. showed that tumor volume was an
independent prognostic factor for poor survival rates in
their study, wherein the patients were divided into groups
according to tumor volume. In multivariate analysis,
patients who had a volume index of ≥36 cm³ were found
to have a mortality rate twice that of other patients (HR
= 1.98, 95% CI: 1.25–3.3; P = 0.0036) [10]. This result
was supported by other studies [11–13]. On the other
hand, a study by Shah et al., in which 345 patients with
endometrial cancer of all tumor types were evaluated
and about 85% of them underwent surgical staging, did
not show tumor size to be predictive of recurrence [14].
Similarly, Ozgul et al. showed that tumor size did not
correlate with survival in 250 surgically staged patients
who had stage 2 endometrial cancers [15]. Moreover,
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tumor size and local surgicopathological factors are not
associated with extrauterine dissemination in patients
with high-risk tumor types. Extrauterine disease may be
observed in patients with serous uterine cancers without
myometrial invasion regardless of tumor size [16,17].
Thus, the relationship between tumor size and prognosis
is unclear. The question of whether this relationship is the
result of the association of tumor size with poor surgical
prognostic factors, especially with lymphatic metastases, or
whether it is the direct effect of tumor size on prognosis still
remains. On the other hand, patients with high-risk tumor
types have high rates of extrauterine spread regardless
of tumor size and the presence of myometrial invasion.
Therefore, the present study included patients with
endometrioid-type endometrial cancer without lymphatic
dissemination and without extrauterine nonnodal spread,
as confirmed in the final pathological examination, and
evaluated the possible effect of tumor size on prognosis.
For this purpose, we aimed to investigate the effect of
tumor size on recurrence and survival rates in patients
with stage I and II endometrioid-type endometrial cancer
who underwent lymphadenectomy.
2. Materials and methods
2.1. Study population
A total of 550 patients were enrolled in the study group. Of
this group, 280 patients had undergone total abdominal
hysterectomy, bilateral salpingo-oophorectomy, and
lymphadenectomy at the University of Health Sciences
Etlik Zübeyde Hanım Gynecologic Oncology Clinic
between January 1993 and May 2013. The remaining 270
patients had undergone total abdominal hysterectomy,
bilateral salpingo-oophorectomy, and lymphadenectomy
between November 1996 and June 2014 at the Hacettepe
University Faculty of Medicine’s Division of Gynecologic
Oncology. Patients were excluded from the study
when they were diagnosed to have nodal/nonnodal
extrauterine spread, nonendometrioid-type tumors,
synchronized tumors, or sarcomatous components of
the tumor in the final pathological examination. Patients
who received neoadjuvant therapy, who did not undergo
lymphadenectomy, or who had missing data on tumor
size were also excluded. Patient data were obtained from
electronic databases, patient files, and pathology reports.
Patients were staged according to the 2009 criteria
described by the International Federation of Obstetrics
and Gynecology (FIGO). Tumor size was obtained from
pathology reports. The largest diameter was accepted as
the tumor size. Institutional review board approval was
obtained from the institution’s local ethical committee
(Approval Code: 2018/228).
2.2. Treatment and follow-up
Frozen section examination was routinely used in the
management of endometrial cancers in both clinics. Staging
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surgery was performed in all patients, except for those with
grade 1 and 2 endometrioid-type tumors, less than 1/2
myometrial invasion, or a tumor size smaller than 2 cm.
The staging surgery was standardized as total abdominal
hysterectomy + bilateral salpingo-oophorectomy +
systematic pelvic and paraaortic lymphadenectomy +
cytological sampling + omentectomy or omental biopsy.
Lymphadenectomy was performed in the majority of
patients by skeletonizing the vessels in the pelvic and
paraaortic region. However, paraaortic lymphadenectomy
was not included in the surgical procedure in a small group
of the patients at the discretion of the surgeon (n = 20).
The necessity and use of adjuvant chemotherapy
and radiotherapy (only radiotherapy or concomitant
chemoradiotherapy), and the type of radiotherapy (vaginal
brachytherapy [VBT] or external beam radiotherapy
[EBRT] plus VBT), were decided by the gynecological
oncology tumor boards in both clinics. The recurrence of the
disease within 1 month after the initial surgical treatment
or, when adjuvant therapy was applied, the progression
of the disease during adjuvant therapy was accepted as
refractory disease. After no signs of the disease were
present in the follow-up visit 1 month after the adjuvant
therapy and during the follow-up period, an occurrence of
treatment failure was defined as recurrence. Recurrences
were accepted as pelvic recurrences when they occurred
in the vaginal wall and/or in the pelvic sidewall below the
pelvic brim, or as upper-abdominal recurrences when they
occurred between the pelvic brim and the diaphragm.
All other recurrences were accepted as extraabdominal
recurrences. Ascites and peritonitis carcinomatosa were
accepted as upper-abdominal recurrences, and recurrences
in the liver parenchyma, bone, and skin were accepted as
extraabdominal recurrences. Recurrences were defined by
clinical, radiological, and histological findings obtained
from pelvic and systemic examinations, abdominal X-rays,
abdominopelvic- and thoracic-computed tomography, or
magnetic resonance imaging. The decision for recurrence
treatment was made by the gynecological oncology tumor
boards in both clinics.
After the surgery or adjuvant therapy, if applied,
patients were followed every 3 months for 2 years, every
6 months until the fifth year, and yearly thereafter. During
the follow-up period, physical examinations of the pelvis,
abdominopelvic imaging with ultrasound, and complete
blood count and blood biochemical tests were performed.
A chest X-ray was utilized yearly or in the case of clinical
suspicion. Thoracic and/or abdominal computerized
tomography was used when needed. CA 125 level was
utilized in the follow-up period, even though it was not
used routinely.
2.3. Statistical analysis
The time from the surgery to the recurrence or to the last
visit was called disease-free survival (DFS). The time from
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the surgery to death due to endometrial cancer or to the
last visit was defined as disease-specific survival (DSS).
The time from the surgery to the recurrence was defined
as time to recurrence (TTR). The Kaplan–Meier method
was used for performing the survival analyses. A logrank test was utilized to determine whether categorical
variables had statistically significant effects on DFS and
DSS. Factors with a P-value of <0.25 were included in
the multivariate analysis. The statistical analyses were
performed using SPSS 11.5 for Windows. The cut-off for
statistical significance was set at P < 0.05.
3. Results
A total of 550 patients with stage I and II endometrioidtype endometrial cancers were included in the study. The
mean age was 58.5 years (range: 33–92 years). Only pelvic
lymphadenectomy without paraaortic lymphadenectomy
was performed in 20 patients (3.6%). The median number
of lymph nodes removed was 39 (range: 1–122), and
more than 20 lymph nodes were removed in 80% of the
patients. The median tumor size was 35 mm (range: 3–335
mm). In the study group, the tumor size was 20 mm or
smaller in 129 patients (23.5%), 21–30 mm in 127 patients
(23.1%), 31-40 mm in 129 patients (23.5%), 41–50 mm in
72 patients (13.1%), and 51 mm and over in 93 patients
(16.9%). According to the FIGO 2009 staging system, 245
patients (44.5%) were diagnosed with a stage IA disease,
271 patients (49.3%) with a stage IB disease, and 34
patients (6.2%) with a stage II disease. According to the
FIGO grading system, 289 patients had a grade 1 disease,
182 had grade 2, and 74 had grade 3. The myometrial
invasion was ≥1/2 in 227 patients, while 55 patients
did not have myometrial invasion. A lymphovascular
invasion was detected in 103 patients, and a cervical
glandular ±stromal involvement was observed in 69
patients. Peritoneal cytology was positive only in 1 patient
(Table 1).
Of the study patients, 187 (34%) received adjuvant
treatments. Among these patients, 175 patients received
only radiotherapy, 4 received concomitant chemotherapy
and radiotherapy, 4 received chemotherapy alone, 3
received sandwich therapy (initial 3 cycles of paclitaxel
and carboplatin followed by radiotherapy, followed by
3 cycles of paclitaxel and carboplatin), and 1 received
chemotherapy followed by radiotherapy (Table 1).
The median follow-up period was 29 months (range:
1–167 months). During this period, 25 patients (4.5%)
had recurrences and 2 patients (0.4%) died of the disease.
Median TTR was 17 months (range: 5–46 months).
Recurrences were present only in the pelvic region in
15 patients. Extraabdominal recurrences were present
in 7 patients. Recurrent disease was defined by clinical,
laboratory, and imaging methods. Clinical, surgical, and

pathological features of the entire cohort and of patients
with recurrence are presented in detail in Table 1.
The 5-year DFS and the 5-year DSS in the entire
cohort were 92% and 99%, respectively. The effects of
the prognostic factors on DFS were evaluated since only
2 patients died during the follow-up period. Older age,
stage II disease, deep myometrial invasion, and receiving
adjuvant radiotherapy were associated with decreased
DFS (Table 2). However, poorer surgical and pathological
factors were present in the group receiving adjuvant
radiotherapy. This group of patients had a higher disease
stage (P < 0.001), deeper myometrial invasion (P < 0.001),
and larger lymphovascular space invasion (P < 0.001);
furthermore, a higher number of patients in this group
had grade 3 disease (P < 0.001). Glandular and/or stromal
cervical invasion was more frequent (P < 0.001) and the
tumor size was larger in this group (P = 0.025). Moreover,
the group receiving adjuvant radiotherapy tended to be
older (P = 0.075). However, the numbers of excised lymph
nodes were similar between the two groups (P = 0.106).
There was not a statistically significant association
between tumor size and DFS. The 5-year DFS for patients
with tumor diameter equal to or less than 35 mm, which
was the median tumor size of the entire group, was 94%,
and it was 89% for patients with a tumor diameter greater
than 35 mm (P = 0.128) (Figure). When the patients were
divided into the groups according to tumor diameter as
≤20 mm, 21–30 mm, 31–40 mm, 41–50 mm, and ≥51
mm, no statistically significant differences were detected
between the groups regarding DFS (Table 2).
The factors detected to have a P-value under 0.25 in the
univariate analysis were included in multivariate analysis.
These factors included age (≥58 years vs. <58 years), stage
(FIGO stage I vs. II) (P < 0.05), tumor size (>35 mm vs. ≤35
mm), depth of myometrial invasion (<1/2 vs. ≥1/2), and
adjuvant radiotherapy (received vs. not received). After the
correlation between these factors was determined, a model
was constructed for multivariate analysis using age, tumor
size, and adjuvant radiotherapy. However, no independent
prognostic factors for DFS could be identified (Table 3).
4. Discussion
The prognostic effect of the tumor size in EC is
controversial. It has not been clarified yet whether there
is an association between tumor size and poor prognostic
factors, or whether poor prognosis occurs solely due
to the prognostic value of the tumor size itself. There
are additional factors complicating assessment of the
prognostic effect of the tumor size, such as the multifocal
presence of the tumor in the endometrial cavity, variable
localization of tumors, and the irregular surface of the
tumor, which complicates measuring the tumor size.
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Table 1. Patients’ characteristics.
Characteristics

Age at initial diagnosis
Disease-free interval (month)
Number of removed lymph nodes
Tumor size at initial diagnosis (mm)
≤20
21–30
Tumor size at
initial diagnosis
31–40
(mm)
41–50
≥51
IA
FIGO 2009 stage
IB
II
1
2
FIGO grade
3
Not reported
No invasion
Depth of
myometrial
<1/2
invasion
≥1/2*
Negative
Lymphovascular
Positive
space invasion
Not reported
Negative
Glandular
Cervical invasion
Stromal
Not reported
Negative
Peritoneal cytology Positive
Not reported
Not received
Adjuvant therapy
Received
Radiotherapy
Concomitant chemoradiotherapy
Type of adjuvant
Chemotherapy
therapy
Sandwich therapy †
Chemotherapy followed by radiotherapy
Negative
Recurrence
Positive
Only pelvic
Only upper abdominal
Only extra abdominal
Site of recurrence
Pelvic + upper abdominal
Pelvic + extra abdominal
Upper abdominal + extra abdominal
Pelvic + upper abdominal + extra abdominal

Entire cohort (n = 550)
n / Mean

% / Median
(range)

58.5
20.2
43.3
37.4
23.5
23.1
23.5
13.1
16.9
44.5
49.3
6.2
52.5
33.1
13.5
0.9
10.0
48.7
41.3
58.7
18.7
22.5
87.5
6.4
6.2
96.4
0.2
3.4
66
34
31.8
0.7
0.7
0.5
0.2
95.5
4.5
2.7
0.5
1.1
0.2
-

58 (33–92)
17 (5–46)
39 (1–122)
35 (3–335)
129
127
129
72
93
245
271
34
289
182
74
5
55
268
227
323
103
124
481
35
34
530
1
19
363
187
175
4
4
3
1
525
25
15
3
6
1
-

Recurrent patients (n = 25)
n / Mean

% / Median
(range)

61
46
42
3
5
8
5
4
11
11
3
7
14
4
5
20
16
4
5
20
2
3
21
0
4
11
14
13
1
-

61 (37–77)
38 (9–118)
40 (15–100)
12
20
32
20
16
44
44
12
28
56
16
20
80
64
16
20
80
8
12
80
0
16
44
56
52
4
-

* Except for uterine serosal invasion
† Three cycles of paclitaxel and carboplatin followed by radiotherapy followed by 3 cycles of paclitaxel and carboplatin.
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Table 2. Univariate analysis of the factors predicting disease-free survival.
5-year disease-free
survival (%)

Factors
Age at initial diagnosis*
Number of lymph nodes*
2009 FIGO stage
Tumor size*

Tumor size

FIGO grade
Depth of myometrial invasion
Lymphovascular space invasion
Cervical invasion ‡
Adjuvant therapy §
Adjuvant radiotherapy

<58 years

96

≥58 years

88

≤38

92

≥39

93

I

94

II

88

≤35 mm

95

≥36 mm

89

≤20 mm

97

21–30 mm

94

31–40 mm

88

41–50 mm

88

≥51 mm

93

1 and 2

92

3

92

<1/2

97

≥1/2 †

86

Negative

91

Positive

95

Negative

93

Positive

88

Not received

94

Received

90

Not received

94

Received

89

P-value
0.005
0.841
0.024
0.128

0.398

0.916
<0.001
0.539
0.341
0.058
0.039

* Median value.
† Except for uterine serosal invasion.
‡ Glandular ±stromal invasion.
§ Radiotherapy and/or chemotherapy.

The relationship between tumor size and poor
prognostic factors, especially lymphatic spread, has been
identified. Lymphatic metastases are considered to increase
as tumor size increases [7–13,16,17]. Vargas et al. evaluated
the Surveillance, Epidemiology, and End Results (SEER)
data in their study, wherein patients were divided into risk
groups based on the presence of lymphatic spread. In that
study, lymphatic involvement was 1.4% in the patients
in the low-risk group who had a tumor size of <2 cm, a
grade 1–2 tumor diagnosed histologically, and myometrial
invasion of <50%. The same study reported that lymphatic
involvement was 6.4% in patients in the high-risk group
(P < 0.001). Moreover, an increase in tumor size was found
to increase lymph node metastases in the multivariate

logistic regression analysis in their study (OR = 1.07, 95%
CI: 1.05–1.09; P < 0.005) [18]. Boyraz et al. showed that
tumor size was associated with lymphatic metastases in
their study including 191 stage 1A EC cases. Lymphatic
spread was detected in 6.28% of the patients with a tumor
size of ≥2 cm, and no lymphatic metastases were observed
in the patients with a tumor size of <2 cm (P = 0.009) [19].
Shah et al. showed that the association between tumor size
and the presence of nodal metastasis was not statistically
significant in the multivariate analysis in their study (OR =
1.3, 95% CI: 1.0–1.8; P > 0.05) [20].
Shinck et al. showed that tumor size greater than 2 cm
was associated with nodal metastases and poor survival
in patients having less than 50% myometrial invasion
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Figure. The 5-year DFS for patients by tumor diameter.
Table 3. Results of the multivariate analyses of the odds ratios in the exact logistic regression model
with recurrence as the dependent variable.
Variables

Odds ratio

95% Confidence
interval

P-value

Age* (≥58 years vs. <58 years)

1.113

0.423–2.928

0.829

Tumor size* (>35 mm vs. ≤35 mm)

1.274

0.526–3.083

0.591

Adjuvant RT (received vs. not received)

1.581

0.626–3.992

0.332

* Median value.

in grade 1 and 2 and stage I endometrial carcinoma [8].
Sozzi et al. found that an increase in tumor size was a
poor prognostic factor for recurrence in their study,
wherein all tumor types were included and patients were
assigned to the study groups based on the European
Society for Medical Oncology (ESMO), European Society
for Radiotherapy & Oncology (ESTRO), and European
Society of Gynaecological Oncology (ESGO) criteria
(n = 1166). The authors reported that recurrence-free
survival was significantly lower in patients with tumor
size greater than 25 mm (P < 0.0001) [21]. Senol et al.
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supported this result with their study (n = 152), in which
they included all histological types of tumors. They found
that tumor size was associated with DFS (OR = 1.2, 95%
CI: 1.016–1.394; P = 0.031). In univariate analysis, the
recurrence rate was 21.9% in the group with tumors
larger than 3.75 cm, whereas it was 3.4% in patients with
tumors smaller than 3.75 cm (OR = 7.9, 95% CI: 2.2–
28.9, P < 0.001) [22]. However, the relationship between
tumor size and oncological outcome in that study could
be explained by the fact that a lymphadenectomy surgery
was not performed and the exact stage of the disease
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could not be defined. Chattopadhyay et al. reported
that an increase in tumor size affected the rates of
recurrence and death in patients who did not undergo
lymphadenectomy [23]. On the other hand, Shah et al.
evaluated 345 patients and included all tumor types in
their study, in which 85% of the patients underwent
surgical staging. They determined that tumor size was
not an independent prognostic factor for recurrence
[20]. Similarly, a retrospective analysis of 250 surgically
staged cases by Ozgul et al. showed that 5-year DFS and
OS did not display differences with increased tumor size
[15]. Moreover, an ESMO-ESGO-ESTRO study stated
that tumor size should not be used as a risk factor in
the risk classification of EC [24]. Tumor size was not a
prognostic factor for DFS in our study, which included
550 patients with stage I and II endometrioid-type
endometrial cancer, and in which nodal spread was
determined by lymphadenectomy.
The retrospective nature was the most important
limitation of the present study. Another limitation was
related to the nature of the tumoral structure, along with

the number of tumoral foci and the localization of the
tumor. However, our strict exclusion criteria allowed
us to create a homogeneous cohort. The strength of the
study was that the confinement of cancer in the uterine
corpus was proven by a lymphadenectomy surgery. The
previously defined association between tumor size and
nodal spread was eliminated by including the patients
who had not undergone lymphadenectomy. The median
number of removed lymph nodes was 39 in the study
group, and more than 20 lymph nodes were removed in
80% of the patients. Moreover, the exclusion of tumors
directly based on the presence of an extrauterine spread
provided a clear assessment of the relationship between
tumor size and survival. Additionally, the study cohort
consisted of a large number of patients.
In conclusion, tumor size was not a risk factor
for recurrence in patients with stage I and II
endometrioid-type endometrial cancer who underwent
lymphadenectomy surgery. Therefore, tumor size
should not be taken into consideration while planning
the treatment protocol in this group.
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